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Abstract
Background: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct
of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical
safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been
based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity
during recruitment for a multi-center, African laboratory reference intervals study.
Methods: Asymptomatic persons, aged 18–60 years, were invited to participate in a cross-sectional study at seven sites
(Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia).
Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical
findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and
urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C.
Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP).
Results and Conclusions: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were
included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on
physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent
process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface
antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted
to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials.
Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for
medical reasons.
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Introduction
Africa has the largest burden of HIV infection and AIDS
worldwide [1]. Laboratory reference intervals for healthy
populations have not been formally established in most African
countries and consequently ‘‘Western’’ laboratory reference
intervals, derived from predominantly Caucasian populations in
Western Europe and the United States, are most often used to
determine whether individual laboratory values should be defined
as normal or out-of-range. Consequently, significant numbers of
potential volunteers are often excluded. Therefore, it is important
to better define the ranges of laboratory values found in healthy
adults likely to enroll in future trials [2,3]. There is some evidence
from small studies conducted in eastern, southern and northern
African populations that differences do exist between ‘‘Western’’
reference intervals and those of adult Africans considered to be
healthy [4–7]. In many studies however, health status was usually
determined by interview alone and did not include physical
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examination or extensive medical history, pregnancy testing or
evaluation for certain clinical conditions.
In order to prepare a vaccine trial laboratory network following
Good Clinical Laboratory Practices (GCLP) and to define a set of
reference intervals suitable for future trial participants, the
International AIDS Vaccine Initiative, the Medical Research
Council in Uganda, the Rwanda-Zambia HIV Research Group,
the Kenyan AIDS Vaccine Initiative and the Kenyan Medical
Research Institute initiated a cross-sectional survey. The laboratory
approach to this study was modeled on the Clinical and Laboratory
Standards Institute (CLSI) guidelines for determining reference
values and intervals for quantitative clinical laboratory tests [8].
This paper presents the recruitment, enrollment, and baseline
morbidities of the 2,990 potential study volunteers.
Methods
Study volunteers
Clinically healthy adult (18–60 years) male and female volun-
teers were enrolled across seven sites in four countries in Eastern
and Southern Africa (Figure 1). All potential volunteers had
received HIV Voluntary Counseling and Testing (VCT) and had a
negative HIV test within three months prior to screening for this
study. Eligibility criteria for this study were similar to those used
for HIV vaccine clinical trials and source populations were
selected as described below. Target enrollments for all sites were
200 or 400 volunteers, depending on site capacity, with equal
numbers of men and women.
Masaka-Medical Research Council (MRC)/ Ugandan
Virus Research Institute (UVRI) Unit on AIDS,
Uganda. Eligible volunteers were selected from a rural general
population cohort enrolled into prospective HIV incidence studies
in preparation for HIV vaccine trials.
Entebbe-UVRI, Uganda. Volunteers for this study were
drawn from community members who: 1) had expressed interest
to participate in future clinical trials, or 2) were prescreened for a
previous HIV vaccine phase 1 clinical trial and were not enrolled
because the trial had completed enrollment.
Kilifi-Kenya Medical Research Institute (KEMRI),
Kenya. Half of this site’s study volunteers were drawn from an
HIV prevalence study in Kilifi Town, and half were selected from
individuals who were enrolled in HIV incidence studies in
preparation for HIV vaccine trials.
Kangemi-Kenya AIDS Vaccine Initiative (KAVI),
Kenya. Volunteers were drawn from an HIV prevalence study
conducted in this peri-urban district of Nairobi in preparation for
HIV incidence studies.
Kenyatta National Hospital (KNH)-KAVI, Kenya. The
majority of volunteers from this site included medical students,
staff and professionals from the KNH medical school and hospital
facility. Community members not affiliated with the facility were
also enrolled.
Lusaka-Zambia Emory HIV Research Program (ZEHRP),
Zambia and Kigali-Projet San Francisco (PSF),
Rwanda. Half of the volunteers from these two sites were
drawn from large prospective studies of long-term, stable sexually
active couples of HIV discordant status (the volunteer’s partner
was HIV positive), and half were drawn from couples identified
during couples’ VCT as concordant HIV-negative (both partners
HIV uninfected).
Study procedures
This study was approved by the Institutional Ethics Committees
(EC) or Institutional Review Boards (IRB) at each participating
institution, including Emory University; all institutions have an
EC/IRB that is registered with the US Office of Human Research
Protection.
Interested potential volunteers were administered a brief
screening questionnaire and symptom-directed examination prior
to enrollment. Volunteers were screened out based on significant
medical history including current clinical symptoms, immunosup-
pressive or corticosteroid medication, chemotherapy, hospitaliza-
tions, surgery or blood transfusions in the six months prior to
screening. Volunteers with splenomegaly (Grade 2+ by Hackett’s
classification) were excluded. Menstruating women were asked to
return in two weeks, and women who reported being pregnant
were not enrolled. Breastfeeding was not an exclusion factor. No
personal identifying information was collected from volunteers
who were screened out prior to enrollment; only age, gender and
reason for ineligibility.
Following screening, written informed consent was obtained
from all eligible volunteers. The consent process included an
explanation and discussion of the study procedures, followed by an
assessment of the potential volunteer’s understanding of the study.
Literacy was not a requirement to participate, and illiterate
volunteers were consented with an independent third party present
to confirm volunteer understanding of the consent process and
study procedures. Only those volunteers who could demonstrate a
satisfactory understanding following the consenting process were
enrolled.
After enrollment, a detailed medical history including repro-
ductive history for women, data on contraception use, investiga-
tion of current medications and demographics (socioeconomic
status, education, environmental exposures, smoking, and drug
and alcohol consumption) were collected from each enrolled
volunteer. A physical examination was performed including
evaluation of vital signs, weight and height. Blood was drawn for
HIV, syphilis and Hepatitis C serology, Hepatitis B antigen,
hematology (complete blood count), clinical chemistry (aspartate
aminotransferase, alanine aminotransferase, total and direct
bilirubin, albumin, total immunoglobulin, creatinine, amylase,
creatinine phosphokinase, lactate dehydrogenase, alkaline phos-
Figure 1. Map of study sites showing source populations,
elevation (meters above sea level) and target enrolment.
doi:10.1371/journal.pone.0002043.g001
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phatase and total protein), and CD4/CD8 T-cell count. The assays
used are outlined in Table 1. The HIV testing algorithm at most
sites used two concurrent rapid HIV tests followed by a
confirmatory ELISA if either rapid test was positive. Urinalysis
was performed, and urine pregnancy tests performed in women. If
needed treatment was not available on-site, volunteers were referred
for appropriate care. Enrolled volunteers were excluded from
subsequent analysis if the laboratory tests revealed that they were
pregnant, positive for HIV-1 or HIV-2, Hepatitis B surface antigen
(HBsAg), antibodies against hepatitis C or RPR (suspected syphilis).
Clinical Laboratories and Assays
For comparative evaluation across centers, standardization of
methods and equipment was deemed essential, and equipment was
chosen that is easy to operate, suitable for lower-volume work and
low-maintenance. For hematology measurements, all sites used the
Beckman Coulter Act5 Diff analyzer (Beckman Coulter, USA).
Biochemistry assays were performed on the VitaLab Selectra E
(VitalScientific, The Netherlands). Both instruments had suppliers
within the region to ensure regular service, maintenance and
reagent supply. The two KAVI sites shared the same laboratory
facilities at the KNH. Five laboratories used the FACSCount (BD
Biosciences) due to its robust performance on the WHO/ NHLS
CDREQAS program across African sites [9]; the KAVI
laboratory used the FACSCalibur flow cytometry system (BD
Biosciences) for CD4 and CD8 counts. To minimize any
contribution of diurnal variation [10], samples for CD4 counts
were taken before noon. The study was conducted according to
principles of GCLP [11] to ensure data reproducibility and
reliability and to prepare site laboratories for the requirements of
trial regulatory bodies.
Quality Assurance and Quality Control
Staff received GCLP training as well as specific technical
training on each analyzer depending on individual site require-
ments [8,11]. All laboratory procedures were formalized in
standard operating procedures. Site audits were conducted prior
to study initiation and during the course of the study to ensure that
pre-defined GCLP standards were maintained. This approach to
establishing laboratories has been described previously by Gilmour
and colleagues [12].
A central reference laboratory in Johannesburg, Republic of
South Africa, assisted with the conduct of cross-validation studies
which included the selection and shipment of proficiency panels of
60 samples from the reference centre to the sites for biochemistry,
hematology and urinanalysis. Results were compared with the
reference laboratory, across technicians, and across sites using the
Bland-Altman [13] and the Percentage Similarity methods [14].
All sites were enrolled on External Quality Assurance (EQA)
programs provided by the National Health Laboratory Service in
South Africa for hematology, chemistry, serology and CD4 counts.
Data
Data were transcribed onto case report forms (CRF) scanned
and emailed to a central server using DataFax (Clinical DataFax
Systems Inc., Hamilton, Canada). Quality assurance included on-
site monitoring of source documents and CRFs, and automated
checks of the electronic data. Data analyses were conducted using
Stata (College Park, TX, USA) and SAS (Cary, NC, USA)
software. Results are descriptive and include tabulations of
screened and enrolled volunteers, and baseline study population
characteristics. Appropriate statistical tests (Wilcoxon rank sum,
Fisher’s exact test) are shown by their p-value.
Table 1. Laboratory assays used for screening enrolled volunteers.
Site Hepatitis B Hepatitis C HIV Pregnancy Syphilis
Kigali-PSF HBsAG ELISA (Abbot-
Murex version 3)
Anti-HCV (Abbot-
Murex version 4)
Rapid HIV 1/2 Determine (Abbott), Rapid
HIV 1/2 Capillus (Trinity Biotech), HIV 1/2
ELISA Vironostika Uni-Form II Ag/Ab
(Biomerieux)
ßhCG reagent strips
(Bayer Multistix 10SG),
Cypress-hCG Dipstrip
RPR Carbon
(Spinreact)
Masaka-MRC Hepanostika HBsAg
Uni-Form II MicroELISA
system (Biomerieux)
Innotest HCV Ab
IV (Innogenetics)
Rapid HIV 1/2 Determine (Abbott), HIV 1/2
ELISA Vironostika Uni-Form II Ag/Ab
(Biomerieux), Murex HIV-1.2.0 ELISA (Abbott),
HIV-1 Western Blot Kit (Calypte biomedical)
ßhCG reagent strips
?show=[sr]?>(Bayer
Multistix 10SG), Hexagon
hCG 1-Step, Cypress
Diagnostics hCG slide
RPR Test (Biotec)
Kilifi-KEMRI Hepanostika HBsAg
Uni-Form II MicroELISA
system (Biomerieux)
Innotest HCV Ab
IV (Innogenetics)
Rapid HIV 1/2 Determine (Abbott), Rapid
HIV 1/2 Uni-Gold (Trinity Biotech), discrepant
results sent for confirmation at KNH-KAVI
ßhCG reagent strips
(Bayer Multistix 10SG)
Macro-Vue RPR Test
(Becton Dickson) with
TPHA confirmation
Kangemi-KAVI Hepanostika HBsAg
Uni-Form II MicroELISA
system (Biomerieux)
Innotest HCV Ab
IV (Innogenetics)
Rapid HIV 1/2 Determine (Abbott), Rapid
HIV 1/2 Uni-Gold (Trinity Biotech), discrepant
results sent for confirmation at KNH-KAVI
ßhCG reagent strips
(Bayer Multistix 10SG),
Hexagon hCG 1-Step
RPR Test (Forest
Diagnostics Ltd)
Kenyatta National
Hospital-KAVI
Hepanostika HBsAg
Uni-Form II MicroELISA
system (Biomerieux)
Innotest HCV Ab
IV (Innogenetics)
Rapid HIV 1/2 Determine (Abbott), Rapid
HIV 1/2 Uni-Gold (Trinity Biotech), HIV 1/2
ELISA Vironostika Uni-Form II Ag/Ab
(Biomerieux), Detect-HIV ELISA (Adaltis, Inc)
ßhCG reagent strips
(Bayer Multistix 10SG),
Hexagon hCG 1-Step
RPR Test (Forest
Diagnostics Ltd)
Entebbe-UVRI Hepanostika HBsAg
Uni-Form II MicroELISA
system (Biomerieux)
Innotest HCV Ab
IV (Innogenetics)
Rapid HIV 1/2 Determine (Abbott), HIV 1/2
ELISA Vironostika Uni-Form II Ag/Ab
(Biomerieux), Murex HIV-1.2.0 ELISA (Abbott),
Cambridge Biotech HIV-1 Western Blot Kit
(Calypte biomedical),
Hexagon hCG 1-Step RPR Test (Biotec)
Lusaka-ZEHRP HBsAG ELISA (Abbot-
Murex version 3)
Anti-HCV (Abbot-
Murex version 4)
Rapid HIV 1/2 Determine (Abbott), Rapid
HIV 1/2 Capillus (Trinity Biotech), Murex
HIV-1.2.0 ELISA (Abbott), HIV 1/2 ELISA
Vironostika Uni-Form II Ag/Ab (Biomerieux)
ßhCG reagent strips
(Bayer Multistix 10SG),
Hexagon hCG 1-Step
RPR Antigen
Suspension (Becton
Dickson)
doi:10.1371/journal.pone.0002043.t001
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Results
Screening and enrollment began in December 2004 and ended
in October 2006. A total of 2990 individuals were screened across
all sites, 1477 women (49.4%) and 1513 men (50.6%). Approx-
imately 20% of screened volunteers were not enrolled with a
further 10% excluded following enrollment (Figure 2). There was
considerable variability in the screen-out and exclusion rates
across sites (Table 2). More women were screened out than men
(22.8% versus 17.6%, Fisher’s exact 2-tailed test: p,0.001), and
this was consistent (though not always statistically significant)
across all sites except Entebbe. Volunteers who were screened out
tended to be older than enrolled volunteers (median age: 30 vs.
28 years, Wilcoxon 2-sample test: p = 0.001).
The most common reasons for screen-outs prior to enrollment
were splenomegaly (89/603, 14.8%), inability to demonstrate
satisfactory comprehension during the informed consent process
(75, 12.4%), hypertension (61, 10.1%), symptoms of upper
respiratory infection (51, 8.5%) and menstruating women who
did not return for re-screening (44, 7.3%). Some volunteers had
more than one reason for exclusion. Most potential volunteers had
been pre-screened for HIV; only 3 potential volunteers were found
to be HIV infected at screening. Table 3 shows the prevalence of
each exclusionary criterion as a proportion of all volunteers
screened. Once enrolled, slightly more men than women were
excluded from analysis (12.8% versus 10.5%, Fisher’s exact 2-
tailed test: p = 0.06), due to a higher prevalence of Hepatitis B
surface antigen (5.5% vs 3.1%, p= 0.002) and Hepatitis C
antibody (6.7% vs. 4.2%, p= 0.005) in men. The final sample of
2107 volunteers was 48.4% women, 51.6% men (Table 2).
Among enrolled volunteers, the prevalence of HBsAg was 4.4%
(106/2387) and of Hepatitis C antibody was 4.0% (95/2387), with
significant variations across sites (Table 3). Dual Hepatitis B and C
infections were uncommon (n = 4). Fifty-five volunteers (2.3%)
were RPR positive, and this did not vary by gender. After 27 self-
reported pregnant women were screened out prior to enrollment,
an additional 1.6% (18/1140) enrolled women were excluded
from analysis because they had positive urine pregnancy tests.
Discussion
AIDS vaccine trials in Africa have not typically employed local
laboratory reference intervals for screening of potential volunteers
and evaluation of adverse events during follow up [personal
communication, C Schmidt]. Several studies in the literature have
suggested that individuals of African origin have different
laboratory reference intervals for a few hematology parameters
compared to Caucasians in industrialized countries. Africans have
been described as having lower platelet counts [6,15,16], lower
neutrophil counts [5,17–19] and lower CD4 T-cell counts [4,20].
Differences in African and Caucasian populations have also been
described for biochemistry, including those for uric acid [21], total
protein [22], globulins and calcium [23]. Much of this research is
older, and reference interval intervals may differ due to differences
Table 2. Screened, enrolled and analyzed volunteers by site and gender.
Kigali-PSF
Kangemi-
KAVI
Kenyatta
National
Hospital -KAVI Entebbe-UVRI Masaka-MRC Lusaka-ZEHRP Kilifi-KEMRI Study Totals
N % N % N % N % N % N % N % N %
Total
Screened 505 – 434 – 214 – 230 – 602 – 497 – 508 – 2990 –
Enrolled 400 79.2% 396 91.2% 204 95.3% 222 96.5% 405 67.3% 393 79.2% 367 72.2% 2387 79.8%
Analyzed 373 73.9% 362 83.4% 197 92.1% 194 84.3% 333 55.3% 352 70.8% 296 58.3% 2107 70.5%
Female
Screened 263 – 215 – 111 – 110 – 293 – 252 – 233 – 1477 –
Enrolled 198 75.3% 193 89.8% 104 93.7% 108 98.2% 183 62.5% 197 78.2% 157 67.4% 1140 77.2%
Analyzed 188 71.5% 176 81.9% 99 89.2% 98 89.1% 146 49.8% 184 75.1% 129 55.4% 1020 69.9%
Male
Screened 242 – 219 – 103 – 120 – 309 – 245 – 275 – 1513 –
Enrolled 202 83.5% 203 92.7% 100 97.1% 114 95.0% 222 71.8% 196 80.3% 210 76.4% 1247 82.4%
Analyzed 185 76.4% 186 84.9% 98 95.1% 96 80.0% 187 60.5% 168 68.6% 167 60.7% 1087 72.2%
doi:10.1371/journal.pone.0002043.t002
Figure 2. Equivalent numbers of men and women aged 18-60
were screened for this study. Among the 2,990 volunteers screened,
2,387 were enrolled, and a further 263 were excluded from analysis
leaving a final study cohort of 2,124 volunteers.
doi:10.1371/journal.pone.0002043.g002
Screening Lab Study
PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e2043
between laboratories (e.g., different test methods), study design
(e.g., sampling conditions, criteria for selection of individuals) and
geographical areas (e.g., differences in temperature, altitude and
endemic diseases). Prior to the work summarized in this paper, few
published studies followed recommended guidelines for the
establishment of reference intervals as suggested by working
groups such as the CLSI. In our study, careful consideration was
given to standardization of analytical methods and instrumenta-
tion. Our study is the first large scale, multi-site study conducted to
the principles of GCLP to characterize local laboratory reference
intervals applicable to potential volunteers in African clinical trials.
Nearly one-third (883/2990, 29.5%) of all persons screened for
the current study were not eligible for analysis. Differences in the
proportion of participants found ineligible both before and after
screening were observed between gender, between countries,
within country and between rural and urban areas (Table 2).
Infectious diseases accounted for more than half of all potential
volunteers who were not eligible for analysis (513/883, 58%),
including Hepatitis B and C (23%), splenomegaly (11%), possible
malaria (6%, data on malaria diagnosis was not collected), STI
(4%) and respiratory tract infections (4%). The high rate of
splenomegaly in the Masaka region of Uganda may suggest
underlying infections, and further investigation is underway. In
many African regions, the combination of parasitic infections such
as schistosomiasis and malaria is responsible for high rates of
splenomegaly; this may help to explain our observed geographical
differences [24,25]. However, hematological disorders and idio-
pathic splenomegaly have also been reported [26]. Hepatitis C
antibody prevalence was unexpectedly high in 2 sites, Masaka
(9%) and Kilifi (8%), and Hepatitis B antigen prevalence was also
high in Kilifi (10%). No confirmatory tests of hepatitis B or C
infections were conducted, and since false positive results have
Table 3. Summary of reasons for screen-outs and exclusion from analysis by site.
Kigali- PSF
Kangemi-
KAVI
Kenyatta
National
Hospital-
KAVI
Entebbe-
UVRI
Masaka-
MRC
Lusaka-
ZEHRP Kilifi- KEMRI Study Totals
N % N % N % N % N % N % N % N %
Total number of volunteers
screened
505 434 214 230 602 497 508 2990
Volunteers screened out * 105 20.8% 38 8.8% 10 4.7% 8 3.5% 197 32.7% 104 20.9% 141 27.8% 603 20.2%
Splenomegaly 7 1.4% 0 0.0% 0 0.0% 2 0.9% 78 12.9% 1 0.2% 1 0.2% 89 3.0%
Hypertension** 6 1.2% 9 2.1% 0 0.0% 0 0.0% 22 3.6% 22 4.4% 2 0.4% 61 2.0%
Flu like symptoms *** 9 1.8% 6 1.4% 0 0.0% 0 0.0% 22 3.6% 7 1.4% 7 1.4% 51 1.7%
Sexually transmitted
infection ****
4 0.8% 0 0.0% 1 0.5% 0 0.0% 21 3.5% 9 1.8% 2 0.4% 37 1.2%
Low body-mass index 13 2.6% 0 0.0% 0 0.0% 1 0.4% 11 1.8% 7 1.4% 1 0.2% 33 1.1%
Acute respiratory infections { 8 1.6% 7 1.6% 1 0.5% 1 0.4% 7 1.2% 3 0.6% 5 1.0% 32 1.1%
HIV antibody positive 1 0.2% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 1 0.2% 1 0.2% 3 0.1%
Other medical history/exam
reasons {
32 6.3% 17 3.9% 6 2.8% 6 2.6% 45 7.5% 39 7.8% 39 7.7% 184 6.2%
Menstruating, did not return 13 2.6% 6 1.4% 1 0.5% 0 0.0% 4 0.7% 18 3.6% 2 0.4% 44 1.5%
Pregnant 0 0.0% 1 0.2% 1 0.5% 0 0.0% 11 1.8% 2 0.4% 12 2.4% 27 0.9%
Unable to complete informed
consent
17 3.4% 3 0.7% 0 0.0% 0 0.0% 27 4.5% 2 0.4% 26 5.1% 75 2.5%
Other non-medical reasons 8 1.6% 1 0.2% 0 0.0% 0 0.0% 8 1.3% 8 1.6% 56 11.0% 81 2.7%
Total number of enrolled
volunteers
400 396 204 222 405 393 367 2387
Volunteers excluded after
enrollment*
27 6.8% 34 8.6% 7 3.4% 28 12.6% 72 17.8% 41 10.4% 71 19.3% 263 11.0%
Hepatitis B antigen positive 13 3.3% 13 3.3% 4 2.0% 10 4.5% 5 1.2% 23 5.9% 38 10.4% 106 4.4%
Hepatitis C antibody positive 10 2.5% 4 1.0% 0 0.0% 10 4.5% 37 9.1% 6 1.5% 28 7.6% 95 4.0%
Syphilis / RPR positive 0 0.0% 12 3.0% 0 0.0% 8 3.6% 21 5.2% 11 2.8% 3 0.8% 55 2.3%
Pregnant 4 1.0% 5 1.3% 1 0.5% 0 0.0% 2 0.5% 1 0.3% 5 1.4% 18 0.8%
Other 1 0 0.0% 3 0.8% 1 0.5% 0 0.0% 11 2.7% 2 0.5% 0 0.0% 17 0.7%
Percentages shown as a proportion of either total screened (above), or total enrolled (below)
* Volunteers may be excluded for multiple reasons therefore columns may sum to .100%
** Systolic blood pressure .140 mm Hg and/or diastolic blood pressure .90 mm Hg
*** Including headaches, cough, fever, suspected and confirmed malaria
**** Active STI, including candidiasis, one possible HSV-1 infection, lower abdominal pain in women, and Bartholin’s abscess
{Including suspected and confirmed TB, pneumonia
{Includes 125/184 (67.9%) medical exclusions not linked to infectious disease (e.g., trauma, diabetes, cancer)
1Includes 4/17 (23.5%) medical exclusions not linked to infectious disease (3 peripheral neuropathy and 1 inebriation at time of visit)
doi:10.1371/journal.pone.0002043.t003
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been reported [27,28] our results require further evaluation.
Another common exclusion factor was the presence of hyperten-
sion. This is consistent with other studies in African populations
where high rates of essential hypertension have been documented
[29,30].
A goal of the study was to include equivalent numbers of men
and women. More women were screened out, and more men were
excluded from analysis, leaving a final cohort with a balanced
gender makeup (48% women). The higher rate of female screen-
outs was at least in part due to the 27 women who screened out
due to reported pregnancy and the 44 who did not return when
rescheduled due to menstruation at screening. Relatively few
women (18) tested positive for pregnancy once enrolled, while the
prevalence of Hepatitis B & C was significantly higher among
enrolled men than women.
The selection of study populations varied by site, and potential
volunteers were frequently selected from participants of ongoing
research, or individuals with a previous interest in participating in
research studies. Therefore, the selection of volunteers for this
study does not represent a random sample of the local residents.
The exception to this is Masaka, where study volunteers were
recruited from the general population after the entire adult
population of three rural villages was informed of upcoming
research activities. The MRC has been working in these
communities for some time, and the many of the residents there
have also participated in previous research activities [31]. The
purpose of this study was to characterize laboratory values in
individuals who might otherwise have participated in vaccine
clinical trials, and this selection bias may therefore limit the
generalizability of these results to the general populations of each
locale.
Data were collected on rainy versus dry season, with some sites
participated in a sub-study that included repeating laboratory tests
in both the rainy and dry seasons. These data will be presented in
a future report. It should be noted that the sites differ significantly
in altitude above sea level, ranging from sea level to 1680 meters
(Figure 1). This difference, as well as others such as demographics
and season will be taken into consideration for future analyses
comparing reference intervals across sites.
Several laboratory implementation lessons were learned during
the course of this study. To assure data were comparable across
sites, significant training of staff in the principles of GCLP and
laboratory management was conducted. Cross validation studies
are essential prior to implementation of study testing to ensure that
all sample processing and analytical procedures are conducted
appropriately. Our work highlighted several problems of both a
pre-analytical and analytical nature. We found that reagent supply
and instrument maintenance were problematic at some sites and
finding proper technical support and in country procurement
sources could be difficult. To maximize cost-effectiveness and
practicality in some cases, we allowed local product availability to
dictate reagent use in some cases in lieu of universal standardi-
zation (Table 1). EQA programs helped maintain satisfactory
analytical performance in real-time, so site visits from the EQA
laboratories are essential to allow for troubleshooting and
additional training.
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